General nature of the STAT3-activated anti-inflammatory response

Journal of Immunology

Volumn 177, Issue 11, 2006, Pages 7880-7888

  El Kasmi, Karim C ^a   Holst, Jeff ^a   Coffre, Maryaline ^a   Mielke, Lisa ^b   De Pauw, Antoine ^a   Lhocine, Nouara ^a   Smith, Amber M ^a   Rutschman, Robert ^a   Kaushal, Deepak ^a   Shen, Yuhong ^c   Suda, Takashi ^d   Donnelly, Raymond P ^e   Myers Jr , Martin G ^f   Alexander, Warren ^b   Vignali, Dario A A ^a   Watowich, Stephanie S ^g   Ernst, Matthias ^b   Hilton, Douglas J ^b   Murray, Peter J ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c ROCKEFELLER UNIVERSITY   (United States)

^d KANAZAWA UNIVERSITY   (Japan)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE RECEPTOR; ERYTHROPOIETIN RECEPTOR; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 6 RECEPTOR; LEPTIN RECEPTOR; RNA; STAT1 PROTEIN; STAT3 PROTEIN;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSDUCTION; IMMUNE RESPONSE; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS; STEM CELL;

EID: 33751555600     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.11.7880     Document Type: Article

References (63)

1. Williams, L. M., G. Ricchetti, U. Sarma, T. Smallie, and B. M. Foxwell. 2004. Interleukin-10 suppression of myeloid cell activation: a continuing puzzle. Immunology 113: 281-292.
2. Murray, P. J. 2006. Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response. Curr. Opin. Pharmacol. 6: 379-386.
3. Moore, K. W., R. de Waal Malefyt, R. L. Coffman, and A. O'Garra. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.
4. Asadullah, K., W. Sterry, and H. D. Volk. 2003. Interleukin-10 therapy: review of a new approach. Pharmacol. Rev. 55: 241-269.
5. Kobayashi, M., M. N. Kweon, H. Kuwata, R. D. Schreiber, H. Kiyono, K. Takeda, and S. Akira. 2003. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest. 111: 1297-1308.
6. Lang, R., D. Patel, J. J. Morris, R. L. Rutschman, and P. J. Murray. 2002. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169: 2253-2263.
7. Matsukawa, A., K. Takeda, S. Kudo, T. Maeda, M. Kagayama, and S. Akira. 2003. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J. Immunol. 171: 6198-6205.
8. Takeda, K., B. E. Clausen, T. Kaisho, T. Tsujimura, N. Terada, I. Förster, and S. Akira. 1999. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 10: 39-49.
9. Williams, L., L. Bradley, A. Smith, and B. Foxwell. 2004. Signal transducer and activator of transcription 3 is the dominant mediator of the anti-inflammatory effects of IL-10 in human macrophages. J. Immunol. 172: 567-576.
10. Murray, P. J. 2005. The primary mechanism of the IL-10-regulated antiinflammatory response is to selectively inhibit transcription. Proc. Natl. Acad. Sci. USA 102: 8686-8691.
11. Kamimura, D., K. Ishihara, and T. Hirano. 2003. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev. Physiol. Biochem. Pharmacol. 149: 1-38.
12. Ito, H., M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, T. Matsumoto, T. Yamamura, J. Azuma, N. Nishimoto, et al. 2004. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996.
13. Ho, A. S., S. H. Wei, A. L. Mui, A. Miyajima, and K. W. Moore. 1995. Functional regions of the mouse interleukin-10 receptor cytoplasmic domain. Mol. Cell Biol. 15: 5043-5053.
14. Riley, J. K., K. Takeda, S. Akira, and R. D. Schreiber. 1999. Interleukin-10 receptor signaling through the JAK-STAT pathway: requirement for two distinct receptor-derived signals for anti-inflammatory action. J. Biol. Chem. 274: 16513-16521.
15. Shen, Y., K. Schlessinger, X. Zhu, E. Meffre, F. Quimby, D. E. Levy, and J. E. Darnell, Jr. 2004. Essential role of STAT3 in postnatal survival and growth revealed by mice lacking STAT3 serine 727 phosphorylation. Mol. Cell. Biol. 24: 407-419.
16. Tebbutt, N. C., A. S. Giraud, M. Inglese, B. Jenkins, P. Waring, F. J. Clay, S. Malki, B. M. Alderman, D. Grail, F. Hollande, et al. 2002. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8: 1089-1097.
17. Croker, B. A., D. Metcalf, L. Robb, W. Wei, S. Mifsud, L. DiRago, L. A. Cluse, K. D. Sutherland, L. Hartley, E. Williams, et al. 2004. SOCS3 is a critical physiological negative regulator of G-CSF signaling and emergency granulopoiesis. Immunity 20: 153-165.
18. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell 84: 431-442.
19. Gingras, S., E. Parganas, A. de Pauw, J. N. Ihle, and P. J. Murray. 2004. Reexamination of the role of suppressor of cytokine signaling 1 (SOCS1) in the regulation of Toll-like receptor signaling. J. Biol. Chem. 279: 54702-54707.
20. Lang, R., A. L. Pauleau, E. Parganas, Y. Takahashi, J. Mages, J. N. Ihle, R. Rutschman, and P. J. Murray. 2003. SOCS3 regulates the plasticity of gp130 signaling. Nat. Immunol. 4: 546-550.
21. Tachiiri, A., R. Imamura, Y. Wang, M. Fukui, M. Umemura, and T. Suda. 2003. Genomic structure and inducible expression of the IL-22 receptor α chain in mice. Genes Immun. 4: 153-159.
22. Pauleau, A. L., R. Rutschman, R. Lang, A. Pernis, S. S. Watowich, and P. J. Murray. 2004. Enhancer-mediated control of macrophage-specific arginase I expression. J. Immunol. 172: 7565-7573.
23. Markowitz, D., S. Goff, and A. Bank. 1988. Construction of a safe and efficient retrovirus packaging cell line. Adv. Exp. Med. Biol. 241: 35-40.
24. Persons, D. A., J. A. Allay, E. R. Allay, R. J. Smeyne, R. A. Ashmun, B. P. Sorrentino, and A. W. Nienhuis. 1997. Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo. Blood 90: 1777-1786.
25. Persons, D. A., M. G. Mehaffey, M. Kaleko, A. W. Nienhuis, and E. F. Vanin. 1998. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol. Dis. 24: 167-182.
26. Szymczak, A. L., C. J. Workman, Y. Wang, K. M. Vignali, S. Dilioglou, E. F. Vanin, and D. A. Vignali. 2004. Correction of multi-gene deficiency in vivo using a single "self-cleaving" 2A peptide-based retroviral vector. Nat. Biotechnol. 22: 589-594.
27. Dunn, S. L., M. Bjornholm, S. H. Bates, Z. Chen, M. Seifert, and M. G. Myers, Jr. 2005. Feedback inhibition of leptin receptor/Jak2 signaling via Tyr1138 of the leptin receptor and suppressor of cytokine signaling 3. Mol. Endocrinol. 19: 925-938.
28. Watowich, S. S., A. Mikami, R. A. Busche, X. Xie, P. N. Pharr, and G. D. Longmore. 2000. Erythropoietin receptors that signal through Stat5 or Stat3 support fetal liver and adult erythropoiesis: lack of specificity of stat signals during red blood cell development. J. Interferon Cytokine Res. 20: 1065-1070.
29. Wooten, D. K., X. Xie, D. Bartos, R. A. Busche, G. D. Longmore, and S. S. Watowich. 2000. Cytokine signaling through Stat3 activates integrins, promotes adhesion, and induces growth arrest in the myeloid cell line 32D. J. Biol. Chem. 275: 26566-26575.
30. Holst, J., K. M. Vignali, A. R. Burton, and D. A. Vignali. 2006. Rapid analysis of T-cell selection in vivo using T cell-receptor retrogenic mice. Nat. Methods 3: 191-197.
31. Croker, B. A., D. L. Krebs, J. G. Zhang, S. Wormald, T. A. Willson, E. G. Stanley, L. Robb, C. J. Greenhalgh, I. Förster, B. E. Clausen, et al. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4: 540-545.
32. Yasukawa, H., M. Ohishi, H. Mori, M. Murakami, T. Chinen, D. Aki, T. Hanada, K. Takeda, S. Akira, M. Hoshijima, et al. 2003. IL-6 induces an antiinflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4: 551-556.
33. De Souza, D., L. J. Fabri, A. Nash, D. J. Hilton, N. A. Nicola, and M. Baca. 2002. SH2 domains from suppressor of cytokine signaling-3 and protein tyrosine phosphatase SHP-2 have similar binding specificities. Biochemistry 41: 9229-9236.
34. Lehmann, U., J. Schmitz, M. Weissenbach, R. M. Sobota, M. Hörtner, K. Friederichs, I. Behrmann, W. Tsiaris, A. Sasaki, J. Schneider-Mergener, et al. 2003. SHP2 and SOCS3 contribute to Tyr-759-dependent attenuation of interleukin-6 signaling through gp130. J. Biol. Chem. 278: 661-671.
35. Nicholson, S. E., D. De Souza, L. J. Fabri, J. Corbin, T. A. Willson, J. G. Zhang, A. Silva, M. Asimakis, A. Farley, A. D. Nash, et al. 2000. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc. Natl. Acad. Sci. USA 97: 6493-6498.
36. Schmitz, J., M. Weissenbach, S. Haan, P. C. Heinrich, and F. Schaper. 2000. SOCS3 exerts its inhibilory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275: 12848-12856.
37. Donnelly, R. P., F. Sheikh, S. V. Kotenko, and H. Dickensheets. 2004. The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukocyte Biol. 76: 314-321.
38. Banks, A. S., S. M. Davis, S. H. Bates, and M. G. Myers, Jr. 2000. Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275: 14563-14572.
39. 985. J. Biol. Chem. 275: 40649-40657.
40. Costa-Pereira, A. P., S. Tininini, B. Strobl, T. Alonzi, J. F. Schlaak, H. Is'harc, I. Gesualdo, S. J. Newman, I. M. Kerr, and V. Poli. 2002. Mutational switch of an IL-6 response to an inlerferon-γ-like response. Proc. Natl. Acad. Sci. USA 99: 8043-8047.
41. Pranada, A. L., S. Metz, A. Herrmann, P. C. Heinrich, and G. Muller-Newen. 2004. Real time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 279: 15114-15123.
42. Ahmed, S. T., and L. B. Ivashkiv. 2000. Inhibition of IL-6 and IL-10 signaling and Stat activation by inflammatory and stress pathways. J. Immunol. 165: 5227-5237.
43. Ahmed, S. T., A. Mayer, J. D. Ji, and L. B. Ivashkiv. 2002. Inhibition of IL-6 signaling by a p38-dependent pathway occurs in the absence of new protein synthesis. J. Leukocyte Biol. 72: 154-162.
44. Niemand, C., A. Nimmesgern, S. Haan, P. Fischer, F. Schaper, R. Rossaint, P. C. Heinrich, and G. Müller-Newen. 2003. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 170: 3263-3272.
45. Boniface, K., F. X. Bernard, M. Garcia, A. L. Gurney, J. C. Lecron, and F. Morel. 2005. IL-22 inhibits epidermal differentiation and induces proinfiammatory gene expression and migration of human keratinocytes. J. Immunol. 174: 3695-3702.
46. Ikeuchi, H., T. Kuroiwa, N. Hiramatsu, Y. Kaneko, K. Hiromura, K. Ueki, and Y. Nojima. 2005. Expression of interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis Rheum. 52: 1037-1046.
47. Wolk, K., S. Kunz, E. Witte, M. Friedrich, K. Asadullah, and R. Sabat. 2004. IL-22 increases the innate immunity of tissues. Immunity 21: 241-254.
48. Hunter, C. A. 2005. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5: 521-531.
49. Hölscher, C., A. Hölscher, D. Rückerl, T. Yoshimoto, H. Yoshida, T. Mak, C. Saris, and S. Ehlers. 2005. The IL-27 receptor chain WSX-1 differentially regulates antibacterial immunity and survival during experimental tuberculosis. J. Immunol. 174: 3534-3544.
50. Hamano, S., K. Himeno, Y. Miyazaki, K. Ishii, A. Yamanaka, A. Takeda, M. Zhang, H. Hisaeda, T. W. Mak, A. Yoshimura, and H. Yoshida. 2003. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19: 657-667.
51. Pearl, J. E., S. A. Khader, A. Solache, L. Gilmartin, N. Ghilardi, F. deSauvage, and A. M. Cooper. 2004. IL-27 signaling compromises control of bacterial growth in mycobacteria-infected mice. J. Immunol. 173: 7490-7496.
52. Rosas, L. E., A. A. Satoskar, K. M. Roth, T. L. Keiser, J. Barbi, C. Hunter, F. J. de Sauvage, and A. R. Satoskar. 2006. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am. J. Pathol. 168: 158-169.
53. Miyazaki, Y., H. Inoue, M. Matsumura, K. Matsumoto, T. Nakano, M. Tsuda, S. Hamano, A. Yoshimura, and H. Yoshida. 2005. Exacerbation of experimental allergic asthma by augmented Th2 responses in WSX-1-deficient mice. J. Immunol. 175: 2401-2407.
54. Villarino, A. V., J. S. Stumhofer, C. J. Saris, R. A. Kastelein, F. J. de Sauvage, and C. A. Hunter. 2006. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 176: 237-247.
55. Kano, A., M. J. Wolfgang, Q. Gao, J. Jacoby, G. X. Chai, W. Hansen, Y. Iwamoto, J. S. Pober, R. A. Flavell, and X. Y. Fu. 2003. Endothelial cells require STAT3 for protection against endotoxin-induced inflammation. J. Exp. Med. 198: 1517-1525.
56. Sano, S., S. Itami, K. Takeda, M. Tarutani, Y. Yamaguchi, H. Miura, K. Yoshikawa, S. Akira, and J. Takeda. 1999. Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. EMBO J. 18: 4657-4668.
57. Hong, F., B. Jaruga, W. H. Kim, S. Radaeva, O. N. El-Assal, Z. Tian, V. A. Nguyen, and B. Gao. 2002. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 110: 1503-1513.
58. Radaeva, S., R. Sun, H. N. Pan, F. Hong, and B. Gao. 2004. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology 39: 1332-1342.
59. Coombes, B. K., Y. Valdez, and B. B. Finlay. 2004. Evasive maneuvers by secreted bacterial proteins to avoid innate immune responses. Curr. Biol. 14: R856-R867.
60. Butcher, B. A., L. Kim, A. D. Panopoulos, S. S. Watowich, P. J. Murray, and E. Y. Denkers. 2005. IL-10-independent STAT3 activation by Toxoplasma gondii mediates suppression of IL-12 and TNF-α in host macrophages. J. Immunol. 174: 3148-3152.
61. de Jonge, W. J., E. P. van der Zanden, F. O. The, M. F. Bijlsma, D. J. van Westerloo, R. J. Bennink, H.-R. Berthoud, S. Uematsu, S. Akira, R. M. van den Wijngaard, and G. E. Boeckxstaens. 2005. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat. Immunol. 6: 844-851.
62. Burdelya, L., M. Kujawski, G. Niu, B. Zhong, T. Wang, S. Zhang, M. Kortylewski, K. Shain, H. Kay, J. Djeu, et al. 2005. Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174: 3925-3931.
63. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10: 48-54.